Skip to main content
Search

Key new drugs help close out 2024

New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.

Welcome to the Fall 2024 Notable New Drugs Report

New treatments target relatively small, hard-to-treat patient populations with big drug spend.

This edition of the report showcases:

  • A first-in-class treatment for both A and B hemophilia which can reduce the frequency of bleeding episodes.
  • A new addition to standard breast cancer therapy with improved outcomes for people with HR-positive breast cancer.
  • A new drug to treat a rare congenital heart disease can reduce the risk of death by 57%.

Don't want to read the full report? Download the summary.

Gain access to this resource

Please complete the form below to get the insights you're looking for.

Related healthcare insights

View all

Article

Aging workforce and the impact on drug spend

An estimated 23% of the workforce will be over age 65 by 2050 – but what does that mean for my drug plan?

Article

2024 in review

Another busy year in pharmacy is coming. Read about top stories in GLP-1s, biosimilars, top spend classes, key regulations and innovations.

Guide

New innovative treatments for hemophilia B, RSV and COPD

Cutting-edge research in gene therapy, mRNA editing and blood enzymes pays off with powerful new advances for these drug classes.